A new technology to combat antimicrobial resistant and biofilm infections

See video


Increased antimicrobial resistance is a health challenge on a global scale that costs 50,000 lives across EU and USA. Moreover, has resulted in an estimated annual cost of € 1.5 billion in healthcare expenses and productivity losses in the EU alone. Moreover, acquired infections in healthcare centres create additional suffering for patients and their families, and can also contribute to increased antibiotic resistance.


  • To develop a new non-existent technological approach combining nanotechnology, antibiotics and physical and chemical strategies to fight infections in healthcare medical devices, such as catheters and prostheses.

Problem to Solve

Over four million patients in the EU acquire healthcare-associated infections (HAI) every year. Usually, HAI are associated with surgical sites and invasive devices, such as vascular access lines, prostheses, catheters and ventilators, that bacteria can colonize growing in biofilms.

These infections are estimated to contribute to roughly 100,000 deaths across the EU. Moreover, current antibiotics are becoming less effective due to increasing bacterial resistance, and there is a lack of new drugs and investment to tackle this challenge. Increased antimicrobial resistance costs 50,000 lives across EU and USA with a prospect of a mortality higher than cancer by 2050.


ThermoShot ™ and FlashShot ™ could help prevent and treat resistant and biofilm infections in two different ways:

  • • ThermoShot ™ combines an antibiotic (amikacin) with a silver nanoparticle that can be heated to produce in situ hyperthermia (40 °C), killing the bacteria.
  • • FlashShot ™ simulates the action of activated neutrophil cells by producing in situ hypochlorous acid, which actively kills bacteria.

Level of Innovation

Both ThermoShot ™ and FlashShot ™ prototypes have been tested in vitro and are an innovative technology that is easy to apply, with a competitive cost-effectiveness rate.


Senior Consultant Infectious Diseases. Coordinator of Antibiotic Resistance Laboratory

Joan Gavaldà

Vall d’Hebron Institut de Recerca

Project leader

Business Angel. Entrepreneur

Santiago Pulido

Assistant Professor

Sergi Colominas

IQS School of Engineering

Research and Tech Services Director

José María Manero

UPC - Universitat Politècnica de Catalunya

Head of the Inorganic Nanoparticles Group (ICN2)

Víctor Puntes

Vall d'Hebron Institut de Recerca and Institut Català de Nanociència i Nanotecnologia

Business Angel “Entrepreneur”. Managing Director & International Business Consultant

Marisa Guitart

MGA, Business Consulting, S.L.

Consultant Orthopedic Surgeon in Infections

Pablo S. Corona

Hospital Universitari Vall d'Hebron

Group leader, Bacterial Infections and Antimicrobial Therapies group

Eduard Torrents

Institut de Bioenginyeria de Catalunya


Global Product Marketing Manager

Raúl Zurita

B. Braun España


Obra social “la Caixa”
Caixa Capital Risc
CI.V 17

Scientific Area

Clinical sciences

Business area

Medical Devices

Research center

Vall d’Hebron Institut de Recerca